Health AI Central
Peer-Reviewed Publication
Br J Pharmacol2026;183(8):1640-1652.April 1, 2026Journal Article

System level network data and models attack cancer drug resistance.

Márk Kerestély1, Dávid Keresztes1, Levente Szarka1, Borbála M Kovács1, Klára Schulc1,2, Dániel V Veres1,3, Peter Csermely1
1Department of Molecular Biology, Semmelweis University, Budapest, Hungary.
2Department of Internal Medicine and Oncology, Division of Oncology, Semmelweis University, Budapest, Hungary.
3Turbine Simulated Cell Technologies, Budapest, Hungary.
PubMed DOI

Abstract

Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small-scale interactomes and signalling network models of drug resistance guide directed drug development. Recently, proteome-wide human interactome and signalling network data have become available, which have been extended by drug-target interact…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.